公开(公告)号：US12127426B2

公开(公告)日：2024-10-22

申请号：US17811232

申请日：2022-07-07

申请人： Samsung Display Co., Ltd.

发明人： Yohan Kim ,  Wonmin Yun ,  Yisu Kim ,  Byoungduk Lee ,  Yoonhyeung Cho

IPC分类号： H10K50/844 ,  C07C233/24 ,  C07C233/33 ,  C07D211/46 ,  C07D249/20 ,  C07D401/12 ,  C08K5/00 ,  C09K3/10 ,  H10K85/60 ,  C08K5/04 ,  C08K5/13 ,  C08K5/16 ,  C08K5/34 ,  H10K59/12 ,  H10K59/35

CPC分类号： H10K50/844 ,  C07C233/24 ,  C07C233/33 ,  C07D211/46 ,  C07D249/20 ,  C07D401/12 ,  C08K5/005 ,  C09K3/10 ,  H10K85/654 ,  H10K85/6572 ,  C08K5/04 ,  C08K5/13 ,  C08K5/16 ,  C08K5/34 ,  H10K59/12 ,  H10K59/35

摘要： Provided are a heterocyclic compound and an electronic apparatus. The electronic apparatus includes: a substrate; an organic light-emitting device on the substrate; and a thin film encapsulation portion sealing the organic light-emitting device, the thin film encapsulation portion including an ultraviolet (UV) stabilizing mixture, and the UV stabilizing mixture including a UV absorbent and a radical scavenger.

公开(公告)号：US11993576B2

公开(公告)日：2024-05-28

申请号：US17424292

申请日：2020-01-21

申请人： Hangzhou Yirui Pharmaceutical Technology Co., Ltd

发明人： Xiaolu Wang ,  Yongzhou Hu ,  Qing Ye ,  Xiuai Hu

IPC分类号： C07D295/205 ,  A61P17/06 ,  C07D207/14 ,  C07D211/46 ,  C07D211/52 ,  C07D211/54 ,  C07D211/58 ,  C07D211/74 ,  C07D211/88 ,  C07D213/42 ,  C07D231/12 ,  C07D233/36 ,  C07D233/64 ,  C07D241/08 ,  C07D277/28 ,  C07D295/155 ,  C07D307/52

CPC分类号： C07D295/205 ,  A61P17/06 ,  C07D207/14 ,  C07D211/46 ,  C07D211/52 ,  C07D211/54 ,  C07D211/58 ,  C07D211/74 ,  C07D211/88 ,  C07D213/42 ,  C07D231/12 ,  C07D233/36 ,  C07D233/64 ,  C07D241/08 ,  C07D277/28 ,  C07D295/155 ,  C07D307/52

摘要： The invention provides an N-benzyl-N-arylsulfonamide derivative, which is an N-benzyl-N-arylsulfonamide compound represented by formula (I) or a pharmaceutically acceptable salt or solvate thereof. The N-benzyl-N-arylsulfonamide derivative is obtained by condensing a substituted nitrobenzene with 5- or 6-membered nitrogen-containing aliphatic heterocycle (the ring B), reducing the nitro group to an amino group, and subjecting the amino group to reductive amination, sulfonamidation; or by subjecting a substituted nitrobenzene to nitro reduction, reductive amination and sulfonamidation, and condensing the resultant intermediate with 5- or 6-membered nitrogen-containing aliphatic heterocycle (the ring B). It has been experimentally demonstrated that the N-benzyl-N-arylsulfonamide derivative of the invention can specifically bind to Kv1.3 potassium channel and inhibit or decrease its activity, and is useful in the treatment of autoimmune diseases caused by abnormal activation of the Kv1.3 potassium channel in human or animals. The invention further provides a medicament or a pharmaceutical composition comprising the N-benzyl-N-arylsulfonamide derivative.

公开(公告)号：US11981636B2

公开(公告)日：2024-05-14

申请号：US17537110

申请日：2021-11-29

申请人： COGNITION THERAPEUTICS, INC.

发明人： Gilbert M. Rishton ,  Gary C. Look ,  Susan M. Catalano

IPC分类号： C07D405/04 ,  C07D205/04 ,  C07D207/08 ,  C07D207/16 ,  C07D211/22 ,  C07D211/46 ,  C07D211/48 ,  C07D241/04 ,  C07D241/08 ,  C07D265/30 ,  C07D401/04 ,  C07D403/06 ,  C07D403/14 ,  C07D405/12 ,  C07D413/14 ,  C07D491/107

CPC分类号： C07D205/04 ,  C07D207/08 ,  C07D207/16 ,  C07D211/22 ,  C07D211/46 ,  C07D211/48 ,  C07D241/04 ,  C07D241/08 ,  C07D265/30 ,  C07D401/04 ,  C07D403/06 ,  C07D403/14 ,  C07D405/04 ,  C07D405/12 ,  C07D413/14 ,  C07D491/107

摘要： The present disclosure relates to novel compounds of Formula I




wherein each of Ra, Rb, Rd and Re is independently H; Rc is selected from the group consisting of H, hydroxyl, halo, alkyl, alkoxy, CF3, SO2CH3, and morpholino, R1 is selected from the group consisting of hydrogen, alkyl, phenyl, or —CH═C(CH3)2; and R2 is specific substituted cyclic amino groups. The invention also discloses pharmaceutical compositions containing the compounds and methods of using the compounds and pharmaceutical compositions for treating neurogenerative diseases, including Alzheimer's disease and cognitive decline.

公开(公告)号：US11926635B2

公开(公告)日：2024-03-12

申请号：US17813382

申请日：2022-07-19

申请人： GEN1E LIFESCIENCES INC.

发明人： Adam Galan ,  Wendy Luo ,  Ritu Lal

IPC分类号： C07D491/107 ,  A61P31/14 ,  C07D207/12 ,  C07D211/42 ,  C07D211/46 ,  C07D239/30 ,  C07D241/08 ,  C07D265/30 ,  C07D267/10 ,  C07D491/048 ,  C07D498/18

CPC分类号： C07D491/107 ,  A61P31/14 ,  C07D207/12 ,  C07D211/42 ,  C07D211/46 ,  C07D239/30 ,  C07D241/08 ,  C07D265/30 ,  C07D267/10 ,  C07D491/048 ,  C07D498/18

摘要： Disclosed herein are p38α mitogen-activated protein kinase inhibitors, pharmaceutical compositions thereof, and therapeutic methods of using the p38α mitogen-activated protein kinase inhibitors.

公开(公告)号：US11905268B2

公开(公告)日：2024-02-20

申请号：US17267649

申请日：2019-08-12

申请人： UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. ,  SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE

发明人： Otto Phanstiel, IV ,  Holly Moots ,  Patrick Maloney ,  Paul Hershberger ,  Satyamaheshwar Peddibhotla

IPC分类号： C07D295/155 ,  A61K45/06 ,  C07D211/46

CPC分类号： C07D295/155 ,  A61K45/06 ,  C07D211/46

摘要： Various embodiments relate to compounds and methods useful for preventing or treating a cancer in a subject. The method may include administering to a subject a composition according to any of the embodiments described herein in an amount effective to inhibit metastatic activity or tumor growth in the subject.

公开(公告)号：US11840497B2

公开(公告)日：2023-12-12

申请号：US17249171

申请日：2021-02-22

申请人： PTC Therapeutics, Inc.

发明人： Orion D. Jankowski ,  Kieron E. Wesson ,  Paul Mollard ,  William D. Shrader

IPC分类号： C07C235/80 ,  C07C235/32 ,  C07C235/78 ,  C07C317/28 ,  C07D207/27 ,  C07D211/46 ,  C07D213/40 ,  C07D233/61 ,  C07D295/13 ,  C07D295/192 ,  C07D265/30 ,  C07D311/66 ,  C07D207/26 ,  C07D213/50 ,  C07D295/116 ,  C07D295/185 ,  A61P21/00 ,  A61P25/00 ,  A61P25/16 ,  A61P27/00 ,  C07D213/51

CPC分类号： C07C235/80 ,  A61P21/00 ,  A61P25/00 ,  A61P25/16 ,  A61P27/00 ,  C07C235/32 ,  C07C235/78 ,  C07C317/28 ,  C07D207/26 ,  C07D207/27 ,  C07D211/46 ,  C07D213/40 ,  C07D213/51 ,  C07D233/61 ,  C07D265/30 ,  C07D295/116 ,  C07D295/13 ,  C07D295/185 ,  C07D295/192 ,  C07D311/66 ,  C07C2601/02 ,  C07C2601/16

摘要： Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, and stroke (MELAS), Kearns-Sayre Syndrome (KSS), are disclosed, as well as compounds useful in the methods of the invention, such as 4-(p-quinolyl)-2-hydroxybutanamide derivatives. Methods and compounds useful in treating other disorders such as amyotrophic lateral sclerosis (ALS), Huntington's disease, Parkinson's disease, and pervasive developmental disorders such as autism are also disclosed. Energy biomarkers useful in assessing the metabolic state of a subject and the efficacy of treatment are also disclosed. Methods of modulating, normalizing, or enhancing energy biomarkers, as well as compounds useful for such methods, are also disclosed.

公开(公告)号：US20230348388A1

公开(公告)日：2023-11-02

申请号：US18214002

申请日：2023-06-26

申请人： Amicus Therapeutics, Inc.

发明人： Kamlesh Sheth ,  Sergey Tesler ,  James Cartwright ,  Clive King ,  Wendy Cross

IPC分类号： C07D211/46

CPC分类号： C07D211/46 ,  C07B2200/13

摘要： Provided are methods of producing Active Pharmaceutical Ingredient (API) grade migalastat hydrochloride, and for purifying intermediate grade migalastat hydrochloride. Further provided are methods of producing [(2R,3S,4R,5S)-1-butyl-2-(hydroxymethyl)piperidine-3,4,5-triol hydrochloride (lucerastat hydrochloride) and other 1-deoxygalactonojirimycin compounds, as well as methods of purifying intermediate grade lucerastat hydrochloride and other 1-deoxygalactonojirimycin compounds.

公开(公告)号：US20230278955A1

公开(公告)日：2023-09-07

申请号：US18117358

申请日：2023-03-03

申请人： KYOTO UNIVERSITY ,  NATIONAL UNIVERSITY CORPORATION TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY

发明人： Mizuki WATANABE ,  Risa ASANO ,  Kazuo NAGASAWA ,  Motonari UESUGI

IPC分类号： C07C401/00 ,  C07D495/04 ,  C07D209/48 ,  C07D211/46 ,  A61K31/593 ,  C07D295/125 ,  A61K31/59 ,  A61P1/16 ,  A61P9/00 ,  A61P3/04 ,  A61P3/10 ,  A61P35/00

CPC分类号： C07C401/00 ,  C07D495/04 ,  C07D209/48 ,  C07D211/46 ,  A61K31/593 ,  C07D295/125 ,  A61K31/59 ,  A61P1/16 ,  A61P9/00 ,  A61P3/04 ,  A61P3/10 ,  A61P35/00 ,  C07C2601/14 ,  C07C2602/24

摘要： The present invention relates to vitamin D3 derivatives of the following formula, wherein each symbol has the same meaning as defined herein, and pharmaceutical or medical use thereof for treating metabolic disease, liver disease, obesity, diabetes, cardiovascular disease, or cancer in a patient in need thereof.

公开(公告)号：US11708326B2

公开(公告)日：2023-07-25

申请号：US17106309

申请日：2020-11-30

申请人： CHEMOCENTRYX, INC.

发明人： Christopher Lange ,  Viengkham Malathong ,  Venkat Reddy Mali ,  Jeffrey McMahon ,  Darren J. McMurtrie ,  Sreenivas Punna ,  Howard S. Roth ,  Rajinder Singh ,  Yu Wang ,  Ju Yang ,  Penglie Zhang

IPC分类号： C07D207/12 ,  A61K45/06 ,  C07D401/12 ,  C07D207/267 ,  C07D211/44 ,  C07D403/12 ,  C07D211/38 ,  C07D451/06 ,  C07D205/12 ,  C07F5/02 ,  C07D405/14 ,  C07D401/14 ,  C07D471/10 ,  C07D211/76 ,  A61P37/02 ,  C07D205/04 ,  C07D213/85 ,  C07D295/088 ,  C07D487/10 ,  C07D405/12 ,  A61K31/40 ,  A61K31/4427 ,  A61K31/445 ,  A61K31/454 ,  A61K31/4545 ,  C07D211/40 ,  C07D211/46

CPC分类号： C07D207/12 ,  A61K31/40 ,  A61K31/445 ,  A61K31/4427 ,  A61K31/454 ,  A61K31/4545 ,  A61K45/06 ,  A61P37/02 ,  C07D205/04 ,  C07D205/12 ,  C07D207/267 ,  C07D211/38 ,  C07D211/40 ,  C07D211/44 ,  C07D211/46 ,  C07D211/76 ,  C07D213/85 ,  C07D295/088 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/12 ,  C07D405/14 ,  C07D451/06 ,  C07D471/10 ,  C07D487/10 ,  C07F5/025

摘要： Compounds are provided that are useful as immunomodulators. The compounds have the following Formula (I):




including stereoisomers and pharmaceutically acceptable salts thereof, wherein Z, L, R1a, R1b, R1c, R1d, R2a, R2b, R2c, R3, R4, R5, R6a, R6b, m and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

公开(公告)号：US11649208B2

公开(公告)日：2023-05-16

申请号：US17860913

申请日：2022-07-08

申请人： SOPHROSYNE PHARMACEUTICALS LIMITED

发明人： Lewis Feldberg ,  Akram Sabouni ,  Thomas R. Bailey ,  Vincent Wing-Fai Tai

IPC分类号： C07D211/46 ,  A61P25/32 ,  C07C333/20 ,  C07C333/04

CPC分类号： C07D211/46 ,  A61P25/32 ,  C07C333/04 ,  C07C333/20

摘要： The disclosure is directed to, in part, compounds, or pharmaceutically acceptable salts or solvates thereof, for modulating the activity of aldehyde dehydrogenase such as ALDH2 and/or methods for treating and/or preventing an alcohol related disorder such as alcohol use disorder, alcohol induced disorder, alcohol abuse, alcohol dependence, alcohol intoxication, alcohol withdrawal, and the like and/or methods for reducing the amount of alcohol consumed, reducing alcoholic cravings, or increasing the percentage of no heavy drinking days for a subject with alcohol use disorder.